СОХРАНЕНИЕ РЕЦЕПТОРОВ ЛПНП — НОВЫЙ ПОДХОД К ТЕРАПИИ ГИПЕРЛИПИДЕМИИ

LDL receptor plays a key role in the metabolism of LDL cholesterol. It have been shown that proprotein convertase subtlisin/kexin type 9 is essential for post-transcriptional regulatation of the cell surface expression of the LDL receptor by participating in its degradation. The data from large epid...

Full description

Bibliographic Details
Main Author: С. С. Бажан
Format: Article
Language:Russian
Published: SINAPS LLC 2013-12-01
Series:Архивъ внутренней медицины
Subjects:
Online Access:https://www.medarhive.ru/jour/article/view/243
_version_ 1797883884522700800
author С. С. Бажан
author_facet С. С. Бажан
author_sort С. С. Бажан
collection DOAJ
description LDL receptor plays a key role in the metabolism of LDL cholesterol. It have been shown that proprotein convertase subtlisin/kexin type 9 is essential for post-transcriptional regulatation of the cell surface expression of the LDL receptor by participating in its degradation. The data from large epidemiological studies indicate that persons with the loss-of-function mutations of PCSK9 have lower LDL level and CHD morbidity. Thus the development of biotechnical/pharmacological agents able to block PCSK9 can be the new option for treatment of patients with severe hyperlipidemia. Currently effectiveness of this approach is studied in large international randomized clinical trials.
first_indexed 2024-04-10T03:58:52Z
format Article
id doaj.art-f4219154a96d4dd8a01584380519e50d
institution Directory Open Access Journal
issn 2226-6704
2411-6564
language Russian
last_indexed 2024-04-10T03:58:52Z
publishDate 2013-12-01
publisher SINAPS LLC
record_format Article
series Архивъ внутренней медицины
spelling doaj.art-f4219154a96d4dd8a01584380519e50d2023-03-13T07:12:04ZrusSINAPS LLCАрхивъ внутренней медицины2226-67042411-65642013-12-0106141710.20514/2226-6704-2013-0-6-14-17256СОХРАНЕНИЕ РЕЦЕПТОРОВ ЛПНП — НОВЫЙ ПОДХОД К ТЕРАПИИ ГИПЕРЛИПИДЕМИИС. С. Бажан0ООО «Амджен»LDL receptor plays a key role in the metabolism of LDL cholesterol. It have been shown that proprotein convertase subtlisin/kexin type 9 is essential for post-transcriptional regulatation of the cell surface expression of the LDL receptor by participating in its degradation. The data from large epidemiological studies indicate that persons with the loss-of-function mutations of PCSK9 have lower LDL level and CHD morbidity. Thus the development of biotechnical/pharmacological agents able to block PCSK9 can be the new option for treatment of patients with severe hyperlipidemia. Currently effectiveness of this approach is studied in large international randomized clinical trials.https://www.medarhive.ru/jour/article/view/243рецептор липопротеинов низкой плотностиpcsk9гиперлипидемия
spellingShingle С. С. Бажан
СОХРАНЕНИЕ РЕЦЕПТОРОВ ЛПНП — НОВЫЙ ПОДХОД К ТЕРАПИИ ГИПЕРЛИПИДЕМИИ
Архивъ внутренней медицины
рецептор липопротеинов низкой плотности
pcsk9
гиперлипидемия
title СОХРАНЕНИЕ РЕЦЕПТОРОВ ЛПНП — НОВЫЙ ПОДХОД К ТЕРАПИИ ГИПЕРЛИПИДЕМИИ
title_full СОХРАНЕНИЕ РЕЦЕПТОРОВ ЛПНП — НОВЫЙ ПОДХОД К ТЕРАПИИ ГИПЕРЛИПИДЕМИИ
title_fullStr СОХРАНЕНИЕ РЕЦЕПТОРОВ ЛПНП — НОВЫЙ ПОДХОД К ТЕРАПИИ ГИПЕРЛИПИДЕМИИ
title_full_unstemmed СОХРАНЕНИЕ РЕЦЕПТОРОВ ЛПНП — НОВЫЙ ПОДХОД К ТЕРАПИИ ГИПЕРЛИПИДЕМИИ
title_short СОХРАНЕНИЕ РЕЦЕПТОРОВ ЛПНП — НОВЫЙ ПОДХОД К ТЕРАПИИ ГИПЕРЛИПИДЕМИИ
title_sort сохранение рецепторов лпнп новый подход к терапии гиперлипидемии
topic рецептор липопротеинов низкой плотности
pcsk9
гиперлипидемия
url https://www.medarhive.ru/jour/article/view/243
work_keys_str_mv AT ssbažan sohraneniereceptorovlpnpnovyjpodhodkterapiigiperlipidemii